PL2683371T3 - Związki i sposoby poprawy zaburzonej funkcji wewnątrzustrojowej fibrynolizy przy zastosowaniu inhibitorów deacetylazy histonowej - Google Patents
Związki i sposoby poprawy zaburzonej funkcji wewnątrzustrojowej fibrynolizy przy zastosowaniu inhibitorów deacetylazy histonowejInfo
- Publication number
- PL2683371T3 PL2683371T3 PL12713772T PL12713772T PL2683371T3 PL 2683371 T3 PL2683371 T3 PL 2683371T3 PL 12713772 T PL12713772 T PL 12713772T PL 12713772 T PL12713772 T PL 12713772T PL 2683371 T3 PL2683371 T3 PL 2683371T3
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- methods
- histone deacetylase
- deacetylase inhibitors
- endogenous fibrinolysis
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000020764 fibrinolysis Effects 0.000 title 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 title 1
- 230000001771 impaired effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161464809P | 2011-03-09 | 2011-03-09 | |
| US201161464776P | 2011-03-09 | 2011-03-09 | |
| US201161628339P | 2011-10-28 | 2011-10-28 | |
| PCT/GB2012/000229 WO2012120262A1 (en) | 2011-03-09 | 2012-03-09 | Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors |
| EP12713772.7A EP2683371B1 (en) | 2011-03-09 | 2012-03-09 | Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2683371T3 true PL2683371T3 (pl) | 2021-04-19 |
Family
ID=45952577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12713772T PL2683371T3 (pl) | 2011-03-09 | 2012-03-09 | Związki i sposoby poprawy zaburzonej funkcji wewnątrzustrojowej fibrynolizy przy zastosowaniu inhibitorów deacetylazy histonowej |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20140051716A1 (pl) |
| EP (1) | EP2683371B1 (pl) |
| CN (2) | CN110063951A (pl) |
| AU (2) | AU2012226586B2 (pl) |
| CA (1) | CA2866333C (pl) |
| DK (1) | DK2683371T3 (pl) |
| ES (1) | ES2842970T3 (pl) |
| HU (1) | HUE053300T2 (pl) |
| MX (1) | MX2013010329A (pl) |
| PL (1) | PL2683371T3 (pl) |
| WO (1) | WO2012120262A1 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201417828D0 (en) * | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| AU2015311905B2 (en) * | 2014-09-03 | 2020-03-05 | Pharmacyclics Llc | Novel salts of 3-[(dimethylamino)methyl)-N-{2-(4-(hydroxycarbamoyl) phenoxy)ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same |
| US20200179381A1 (en) * | 2016-04-08 | 2020-06-11 | Cereno Scientific Ab | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation |
| PL3439649T3 (pl) * | 2016-04-08 | 2024-03-18 | Cereno Scientific Ab | Preparaty farmaceutyczne o opóźnionym uwalnianiu zawierające kwas walproinowy i ich zastosowanie |
| TWI659949B (zh) | 2016-05-16 | 2019-05-21 | 臺北醫學大學 | 組蛋白去乙醯酶6抑制劑及其用途 |
| JP7373991B2 (ja) | 2016-07-15 | 2023-11-06 | ビラクタ セラピューティクス,インク. | 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤 |
| CN112004537A (zh) | 2018-01-09 | 2020-11-27 | 穿梭药业公司 | 用于治疗人疾病的选择性组蛋白去乙酰化酶抑制剂 |
| KR20220034736A (ko) | 2019-05-31 | 2022-03-18 | 비락타 서브시디어리 인크. | 히스톤 데아세틸라제 억제제를 사용하여 바이러스 관련 암을 치료하는 방법 |
| CN118772107A (zh) * | 2023-04-06 | 2024-10-15 | 微境生物医药科技(上海)有限公司 | Hdac抑制剂及其用途 |
| KR102859315B1 (ko) * | 2024-02-27 | 2025-09-12 | 주식회사 아이피에스바이오 | 히스톤 탈아세틸효소 저해제를 포함하는 다중 글루타민 질병의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0300111B1 (en) * | 1987-07-22 | 1991-10-16 | Farvalsa AG | A moisture stable solid valproic acid formulation and a method of preparing the same |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| USRE38506E1 (en) | 1991-10-04 | 2004-04-20 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| IT1283637B1 (it) | 1996-05-14 | 1998-04-23 | Italfarmaco Spa | Composti ad attivita' antinfiammatoria ed immunosoppressiva |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| WO2002030879A2 (en) | 2000-09-29 | 2002-04-18 | Prolifix Limited | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors |
| WO2002055017A2 (en) * | 2000-11-21 | 2002-07-18 | Wake Forest University | Method of treating autoimmune diseases |
| ITMI20011733A1 (it) * | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
| OA12790A (en) | 2002-03-13 | 2006-07-10 | Janssen Pharmaceutica Nv | New inhibitors of histone deacetylase. |
| AU2003218735B2 (en) | 2002-03-13 | 2009-03-12 | Janssen Pharmaceutica N.V. | Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
| PL205531B1 (pl) | 2002-03-13 | 2010-04-30 | Janssen Pharmaceutica Nv | Pochodna karbonyloaminowa, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna |
| EP1591109B1 (en) | 2004-04-30 | 2008-07-02 | TopoTarget Germany AG | Formulation comprising histone deacetylase inhibitor exhibiting biphasic release |
| ITMI20040876A1 (it) * | 2004-04-30 | 2004-07-30 | Univ Degli Studi Milano | Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari |
| US7737184B2 (en) | 2004-07-12 | 2010-06-15 | Merck Sharp & Dohme Corp. | Histone deacetylase inhibitors |
| EP1768955A1 (en) | 2004-07-12 | 2007-04-04 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide derivatives as inhibitors of histone deacetylase |
| JP2008505969A (ja) | 2004-07-12 | 2008-02-28 | メルク エンド カムパニー インコーポレーテッド | ヒストン脱アセチル化酵素の阻害剤 |
| AU2005271842A1 (en) | 2004-07-12 | 2006-02-16 | Merck Sharp & Dohme Corp. | Histone deacetylase inhibitors |
| WO2006020004A2 (en) | 2004-07-19 | 2006-02-23 | Merck & Co., Inc. | Histone deacetylase inhibitors |
| WO2006010750A1 (en) | 2004-07-28 | 2006-02-02 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| US8569277B2 (en) * | 2004-08-11 | 2013-10-29 | Palo Alto Investors | Methods of treating a subject for a condition |
| AR050926A1 (es) | 2004-09-03 | 2006-12-06 | Astrazeneca Ab | Derivados de benzamida como inhibidores de la histonadesacetilasa(hdac) |
| GB0500828D0 (en) | 2005-01-15 | 2005-02-23 | Astrazeneca Ab | Benzamide derivatives |
| WO2006117165A2 (en) * | 2005-05-02 | 2006-11-09 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Means and methods for the treatment of head injuries and stroke |
| EP1743654A1 (en) * | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
| AU2006287378A1 (en) * | 2005-09-07 | 2007-03-15 | Braincells, Inc. | Modulation of neurogenesis by HDac inhibition |
| PL1937650T3 (pl) * | 2005-09-08 | 2011-11-30 | Mei Pharma Inc | Związki heterocykliczne |
| ES2366132T3 (es) | 2005-10-27 | 2011-10-17 | Janssen Pharmaceutica Nv | Derivados del ácido escuárico como inhibidores de la histona desacetilasa. |
| US8114876B2 (en) | 2006-01-19 | 2012-02-14 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| WO2007082882A1 (en) | 2006-01-19 | 2007-07-26 | Janssen Pharmaceutica N.V. | Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase |
| CN101370791B (zh) | 2006-01-19 | 2012-05-02 | 詹森药业有限公司 | 作为组蛋白脱乙酰基酶抑制剂的吡啶和嘧啶衍生物 |
| JP5225104B2 (ja) | 2006-01-19 | 2013-07-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 新しい、ヒストンデアセチラーゼのインヒビターとしてのアミノフェニル誘導体 |
| JP5225103B2 (ja) | 2006-01-19 | 2013-07-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストン・デアセチラーゼの新規なインヒビターとしてのヘテロシクリルアルキル誘導体 |
| CA2631874C (en) | 2006-01-19 | 2014-11-18 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| WO2007084775A2 (en) * | 2006-01-20 | 2007-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulation of suppressor t cell activation |
| AU2007234380A1 (en) * | 2006-04-06 | 2007-10-11 | Novartis Ag | Combination of organic compounds |
| GB2454118B (en) * | 2007-06-06 | 2010-06-02 | Univ Maryland | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| US20090270497A1 (en) | 2008-04-24 | 2009-10-29 | Pharmacyclics, Inc. | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors |
| CN101897687B (zh) * | 2009-05-26 | 2012-07-04 | 中国科学院上海生命科学研究院 | 丙戊酸钠治疗肝脏炎症相关疾病的新用途 |
| WO2011113013A2 (en) * | 2010-03-11 | 2011-09-15 | Hemaquest Pharmaceuticals, Inc. | Methods and compositions for treating viral or virally-induced conditions |
-
2012
- 2012-03-09 US US14/003,780 patent/US20140051716A1/en not_active Abandoned
- 2012-03-09 CN CN201910075753.1A patent/CN110063951A/zh active Pending
- 2012-03-09 ES ES12713772T patent/ES2842970T3/es active Active
- 2012-03-09 CN CN201280012475.1A patent/CN103648492A/zh active Pending
- 2012-03-09 CA CA2866333A patent/CA2866333C/en active Active
- 2012-03-09 HU HUE12713772A patent/HUE053300T2/hu unknown
- 2012-03-09 DK DK12713772.7T patent/DK2683371T3/da active
- 2012-03-09 EP EP12713772.7A patent/EP2683371B1/en active Active
- 2012-03-09 AU AU2012226586A patent/AU2012226586B2/en active Active
- 2012-03-09 WO PCT/GB2012/000229 patent/WO2012120262A1/en not_active Ceased
- 2012-03-09 PL PL12713772T patent/PL2683371T3/pl unknown
- 2012-03-09 MX MX2013010329A patent/MX2013010329A/es unknown
-
2015
- 2015-12-01 US US14/955,922 patent/US20170020874A1/en not_active Abandoned
-
2017
- 2017-05-05 AU AU2017203028A patent/AU2017203028B2/en active Active
-
2020
- 2020-03-02 US US16/806,594 patent/US20210060014A1/en not_active Abandoned
-
2022
- 2022-05-17 US US17/746,537 patent/US20230094176A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HUE053300T2 (hu) | 2021-06-28 |
| CA2866333A1 (en) | 2012-09-13 |
| EP2683371B1 (en) | 2020-10-21 |
| AU2017203028B2 (en) | 2018-11-15 |
| AU2017203028A1 (en) | 2017-05-25 |
| AU2012226586B2 (en) | 2017-04-13 |
| CN103648492A (zh) | 2014-03-19 |
| US20140051716A1 (en) | 2014-02-20 |
| ES2842970T3 (es) | 2021-07-15 |
| US20230094176A1 (en) | 2023-03-30 |
| CN110063951A (zh) | 2019-07-30 |
| WO2012120262A1 (en) | 2012-09-13 |
| US20170020874A1 (en) | 2017-01-26 |
| EP2683371A1 (en) | 2014-01-15 |
| DK2683371T3 (da) | 2021-01-18 |
| AU2012226586A1 (en) | 2013-10-03 |
| CA2866333C (en) | 2020-12-29 |
| US20210060014A1 (en) | 2021-03-04 |
| MX2013010329A (es) | 2014-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259958B (en) | Heterocyclic glutaminase inhibitors | |
| PL2683371T3 (pl) | Związki i sposoby poprawy zaburzonej funkcji wewnątrzustrojowej fibrynolizy przy zastosowaniu inhibitorów deacetylazy histonowej | |
| IL253259A0 (en) | Inhibitors of histone demethylases | |
| TWI560172B (en) | Neprilysin inhibitors | |
| EP2680694A4 (en) | INHIBITORS OF HISTONE DEACETYLASE | |
| EP2678018A4 (en) | COMBINATION OF CHINESE HEMMER AND USES THEREOF | |
| IL230917A0 (en) | 1dyrk inhibitors and uses thereof | |
| SI2670401T1 (sl) | Postopki uporabe inhibitorjev ALK | |
| ZA201206456B (en) | Uses of dgati inhibitors | |
| IL227379A0 (en) | Histone deacetylase inhibitors and compositions and methods of using them | |
| SG11201400102WA (en) | Inhibitors of nedd8-activating enzyme | |
| ZA201306415B (en) | Peptide deformylase inhibitors | |
| ZA201404044B (en) | Peptide deformylase inhibitors | |
| HK1187409A (en) | Peptide deformylase inhibitors | |
| HK1191805A (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| HK1192727A (en) | Combination of kanase inhibitors and uses thereof |